Growth Hormone News and Research

RSS

Growth hormone (GH) is a protein-based peptide hormone. It stimulates growth, cell reproduction and regeneration in humans and other animals. Growth hormone is a 191-amino acid, single-chain polypeptide that is synthesized, stored, and secreted by the somatotroph cells within the lateral wings of the anterior pituitary gland.

British post-menopausal women less likely to access appropriate treatment for vaginal atrophy

New data, published today in Menopause International, suggests that post-menopausal women in Britain are experiencing less sex, and less satisfying sex compared to their European and North American counterparts1, because they are considerably less likely to access appropriate treatment for a common, taboo condition called vaginal atrophy1.

20 Jun 2013

AACE applauds the American Medical Association for recognizing obesity as disease state

The American Association of Clinical Endocrinologists (AACE) applauds the American Medical Association (AMA) House of Delegates for its action today to approve a resolution recognizing obesity as a disease state requiring a range of interventions to advance obesity treatment and prevention. AACE, the sponsor of the resolution, was joined by specialty and state medical societies in advocating for recognition of obesity as a disease state, including The Endocrine Society, American College of Cardiology, American College of Surgeons, American Urological Association, and the Texas State Delegation among many others.

19 Jun 2013

Ambrx, ZMC partner to develop and commercialize ARX788 for treatment of Her2-positive breast cancer

Ambrx and Zhejiang Medicine Co. Ltd. today announced that they have formed a collaboration to develop and commercialize ARX788, Ambrx's most advanced internally developed site-specific antibody drug conjugate targeting Her2-positive breast cancer.

17 Jun 2013

New data on PROLOR Biotech's hGH-CTP and MOD-6030 to be presented at ENDO 2013

PROLOR Biotech, Inc., today announced that the company will present new data on its long-acting human growth hormone (hGH-CTP) in Phase III development for the treatment of growth hormone deficiency and its long acting oxyntomodulin (MOD-6030) in preclinical development for the treatment of obesity and type 2 diabetes at ENDO 2013, the 95th Annual Meeting of the Endocrine Society.

13 Jun 2013

New study explores effects of growth hormone on the skin

It seems everyone's talking about human growth hormone these days. CNN, Fox News, The Today Show, The Dr. Oz Show, Shape magazine… even Vanity Fair have all done features on hGH. Many of Hollywood's "elite" have been visiting some of the most expensive clinics in the world for controversial hGH therapy. Why? Because they believe human growth hormone can reduce wrinkles, tighten saggy skin, decrease body fat, increase lean muscle mass, boost energy, rev up sex drive, and make you look and feel decades — not years, but DECADES — younger.

11 Jun 2013

Study reveals connection between impaired hGH levels, sleep fragmentation

If you've heard that Growth Hormone therapy can reduce wrinkles, tighten saggy skin, decrease body fat, increase lean muscle mass, boost energy, rev up sex drive, and make you look and feel decades — not years, but DECADES — younger, you can now add one more ostensible benefit to the list… a good night's sleep!

5 Jun 2013

PROLOR Biotech announces initiation of hGH-CTP Phase III trial in growth hormone deficient adults

PROLOR Biotech, Inc., a company developing next-generation biobetter therapeutic proteins, today announced the initiation of a pivotal Phase III clinical trial of hGH-CTP, the company's proprietary version of human growth hormone, in growth hormone deficient adults.

4 Jun 2013

Viewpoints: Slowing health costs; What causes genetic testing to be so expensive; Iowa governor offers Medicaid supports a 'glimmer of hope'

We have done it. We have decreased the increase in the cost of healthcare. ... Is this decline the desperately needed bend in the healthcare cost curve or just the impact of the depressed economy? ... A slower growth of healthcare cost would mean less burden on the individual family, freeing that family to invest in and live a higher quality of life.

22 May 2013

Aileron Therapeutics concludes first-in-human study of ALRN-5281 Stapled Peptide drug

Aileron Therapeutics, Inc. today announced the completion of the first-in-human study of its lead Stapled Peptide drug, ALRN-5281, a proprietary, long-acting growth-hormone-releasing hormone (GHRH) agonist for treating orphan endocrine disorders, including adult growth hormone (GH) deficiency and human immunodeficiency virus (HIV) lipodystrophy, as well as broader patient populations involving a wide variety of metabolic/endocrine diseases.

7 May 2013

New FDA-approved method for detecting diabetic neuropathy

Details of a new method to detect diabetic neuropathy in patients in less than five minutes using their sweat glands was presented today at the American Association of Clinical Endocrinologists 22nd Annual Scientific and Clinical Congress in Phoenix, Arizona by Aaron I. Vinik, M.D., Ph.D., F.C.P., M.A.C.P., F.A.C.E., Professor of Medicine and Director of Research and the Neuroendocrine Unit at Eastern Virginia Medical School.

4 May 2013

Case report reveals that sugar substitutes may adversely affect endocrine health

It's a known fact that drinking too many sugary drinks can lead to obesity and diabetes, but sugar substitutes may adversely affect your endocrine health, according to a case report presented at the American Association of Clinical Endocrinologists 22nd Annual Scientific and Clinical Congress.

4 May 2013

Study: About 42% of screened veterans with blast injuries have irregular hormone levels

Up to 20 percent of veterans returning from Afghanistan and Iraq have experienced at least one blast concussion. New research suggests that nearly half these veterans may have a problem so under-recognized that even military physicians may fail to look for it.

23 Apr 2013

Aeterna enters into agreements to transfer manufacturing license for Cetrotide to Merck KGaA

Aeterna Zentaris Inc. today announced that its German subsidiary has entered into binding agreements with various partners and licensees with respect to the manufacturing rights and obligations for its Cetrotide® product.

22 Apr 2013

AACE publishes comprehensive diabetes management algorithm to treat prediabetes, T2DM patients

The American Association of Clinical Endocrinologists today announced the publication of its comprehensive diabetes management algorithm created to guide primary care physicians, endocrinologists and other health care professionals in the treatment of prediabetes and type 2 diabetes mellitus patients.

20 Apr 2013

Updated guidelines for metabolic and bariatric surgery

Significant new scientific evidence published over the last four years has prompted three major medical societies to change its guidance on who should get metabolic and bariatric surgery and which methods should be used.

6 Apr 2013

USPTO issues Notice of Allowance on Antares Pharma's patent application for VIBEX QS device

Antares Pharma, Inc. announced that it has received a Notice of Allowance from the U.S. Patent Trade Office on a patent application for the VIBEX QuickShot device, the latest advancement in its proprietary line of VIBEX auto-injector systems.

5 Apr 2013

Study: Growth hormone therapy reverses growth problems in pediatric patients with kidney failure

Growth hormone therapy can help reverse growth problems in children with kidney failure, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology.

5 Apr 2013

Johnson Electric introduces miniature medication dosing system technology

Johnson Electric today announced a miniature medication dosing system technology under the Johnson Medtech brand. The subsystem platform provides a high precision dosing accuracy over device operational life.

24 Mar 2013

DSMB recommends discontinuation of Aeterna Zentaris’ perifosine Phase 3 study for MM

Aeterna Zentaris Inc. today announced that an independent Data Safety Monitoring Board has recommended discontinuing the ongoing Phase 3 study comparing the efficacy and safety of perifosine to placebo when combined with bortezomib (Velcade) and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.

12 Mar 2013

FDA accepts Antares Pharma's New Drug Application for OTREXUP

Antares Pharma, Inc. today announced that the New Drug Application for OTREXUP, a potential new product for the subcutaneous delivery of methotrexate using Medi-Jet technology, has been accepted by the U.S. Food and Drug Administration indicating that the application is sufficiently complete to permit a substantive review.

27 Feb 2013